Vaxart Chairman Michael J. Finney, Ph.D., To Retire From Board Of Directors And Science And Technology Committee Effective September 30, 2025

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant pill vaccines using its proprietary delivery platform, has announced that Michael J. Finney, Ph.D., Chairman of the Board, will retire from the Company’s Board of Directors and Science and Technology Committee. His retirement will take effect on September 30, 2025, following a distinguished period of service. During his tenure, Dr. Finney provided strategic guidance and scientific oversight as the company advanced its vaccine programs. 

His contributions helped shape Vaxart’s direction as it continues to develop innovative oral vaccine candidates aimed at transforming preventive healthcare. The Board of Directors is scheduled to meet later this month to review leadership structure, board composition, and other governance matters. As part of this process, stockholder feedback will be considered to ensure that the company remains well-positioned to support its scientific and business objectives going forward.

Mr. Finney stated, “It has been a profound privilege to serve as Vaxart’s Chairman and be a part of this incredible Company’s journey for so many years. I am immensely proud of what we have accomplished together, and I have the utmost confidence in the team's ability to continue their vital work in advancing its oral pill vaccine platform. I look forward to watching Vaxart's future successes.”

Steven Lo, Chief Executive Officer of Vaxart, commented, “On behalf of the Board and the entire Vaxart team, I want to express our deepest gratitude to Mike for his leadership, wisdom, and steadfast dedication. His contributions have been invaluable to Vaxart’s growth and mission. We wish him all the best.”